Merck’s Gardasil 9 Receives the US FDA’s Approval to Prevent HPV-Related Head and Neck Cancers

 Merck’s Gardasil 9 Receives the US FDA’s Approval to Prevent HPV-Related Head and Neck Cancers

Merck’s KEYTRUDA (pembrolizumab) Receives CHMP Recommendation for 1L Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Shots:

  • The US FDA has approved an expanded indication for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58
  • The FDA has approved the therapy under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. The continued approval for the indication may be contingent upon verification and description of clinical benefit in a confirmatory trial while the trial is undergoing
  • Gardasil 9 is (human papillomavirus 9-valent vaccine, recombinant) is now approved for the prevention of HPV-related cervical, vaginal, vulvar, anal, oropharyngeal, and other head and neck cancers for females and males aged 9-45yrs.

Click here to read full press release/ article | Ref: Merck | Image: Merck

Related News: Merck’s Gardasil 9 Receives FDA’s Expanded Label Approval for Prevention of HPV Related Disorders

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post